PRESS RELEASE FROM NATURE CLINICAL PRACTICE ONCOLOGY
This press release is copyrighted to Nature Clinical Practice Oncology.
PLEASE CITE NATURE CLINICAL PRACTICE ONCOLOGY AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO THE JOURNAL'S SITE: <http://www.nature.com/ncponc/>
Warning: This document, and the Nature Clinical Practice paper to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of Nature’s content may be guilty of insider trading under the US Securities Exchange Act of 1934.
Diagnosis and treatment insights for an unusual childhood cancer syndrome
DOI: 10.1038/ncponc0719
An unusual case of a young girl with a colon cancer syndrome caused by recessive mutations in the mismatch repair gene MSH6 is described in the February issue of Nature Clinical Practice Oncology. Individuals with mutations in MSH6 are at an increased risk of developing cancer; however, a childhood cancer syndrome caused by these mutations has only recently been recognized.
In this article, Richard Scott and colleagues report how a 13-year-old girl who was treated for a brain tumor and leukemia was subsequently diagnosed with multiple colon cancers and skin lesions, despite an absence of hereditary colon cancer. Recessive mutations in the MSH6 gene were identified in this patient and she was successfully treated with surgery and chemotherapy.
This case study broadens the tumor spectrum associated with recessive MSH6 mutations and discusses the implications for treatment in such individuals. Many mismatch repair deficiency syndromes are treated with the drug temozolomide, but preclinical and clinical data show that it can cause resistance and may promote further genetic abnormality. Mutations in MSH6 and other mismatch repair genes should be considered in any child presenting with malignancy and abnormal skin pigmentation. Early diagnosis is important so that genetic testing and screening can be offered to relatives, and could also help avoid ineffective chemotherapeutic agents such as temozolomide.
Author contact:
Richard Scott (Institute of Cancer Research, Surrey, UK)
Tel: +44 208 7224 455; E-mail: [email protected]
Editor contact:
Lisa Hutchinson (Editor, Nature Clinical Practice Oncology)
Tel: +44 20 7843 4837; Email: [email protected]
The Nature Clinical Practice journals:
Nature Clinical Practice journals deliver timely, authoritative interpretations of key research developments, translating the latest findings into clinical practice. Each of the eight titles in the series is published monthly. Content includes editorial and opinion pieces, highlights from the current literature, commentaries on the application of recent research to practical patient care, thorough reviews, and in-depth case studies. The journals’ Editors-in-Chief and international advisory boards ensure comprehensive coverage throughout the year, with discussion of topical issues included as soon as possible after publication of the original research.
The first four Nature Clinical Practice journals were launched in November 2004 and a further four were launched in November 2005. For a full list of journal titles and for more information, visit www.nature.com/clinicalpractice
PRESS CONTACTS
Ruth Francis, Nature London
Tel: +44 20 7843 4562; E-mail [email protected]
Katherine Anderson, Nature London
Tel: +44 20 7843 4502; E-mail: [email protected]
About Nature Publishing Group
Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, was first published in 1869. Other publications include Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through [email protected] and scientific career information through Naturejobs.
NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to <www.nature.com>
